Trials / Unknown
UnknownNCT05223595
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
A Phase Ib Study to Investigate the Safety, Tolerability and Preliminary Antitumor Activity of Gentuximab in Combination With Almonertinib in Patients With EGFR Mutation-positive Metastatic Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, open label study to investigate the safety and efficacy of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gentuximab | Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily. |
Timeline
- Start date
- 2021-04-02
- Primary completion
- 2023-09-30
- Completion
- 2024-01-30
- First posted
- 2022-02-04
- Last updated
- 2022-02-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05223595. Inclusion in this directory is not an endorsement.